Evidence map›Paper›PMID 31563573›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

Matt S Zinter, Brent R Logan, Caitrin Fretham, Anil Sapru, Allistair Abraham, Mahmoud D Aljurf, Staci D Arnold, Andrew Artz, Jeffery J Auletta, Saurabh Chhabra and 13 more

Abstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Matt S ZinterDepartment of Pediatrics, Division of Critical Care Medicine, University of California, San Francisco, San Francisco, California. Electronic address: matt.zinter@ucsf.edu.
Brent R LoganDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
Caitrin FrethamCenter for International Blood and Marrow Transplant Research, Milwaukee, WI, USA; National Marrow Donor Program, Minneapolis, MN, USA.
Anil SapruDepartment of Pediatrics, Division of Critical Care Medicine, University of California, Los Angeles, Los Angeles, California.
Allistair AbrahamDivision of Blood and Marrow Transplantation, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington DC, USA.
Mahmoud D AljurfDepartment of Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Staci D ArnoldChildren's Healthcare of Atlanta, Emory University, Atlanta, GA, USA.
Andrew ArtzDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
Jeffery J AulettaHematology, Oncology and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA.
Saurabh ChhabraDivision of Hematology/Oncology, Medical College of Wisconsin, Wisconsin, Milwaukee, WI, USA.
Edward CopelanBlood and Marrow Transplantation Program, Arthur G. James Cancer Institute, Columbus, OH, USA.
Christine DuncanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Robert P GaleDepartment of Medicine, Division of Experimental Medicine, Hematology Research Centre, Imperial College London, London, United Kingdom.
Eva GuinanCenter for Clinical and Translational Research, Dana-Farber Cancer Institute, Boston, MA, USA.
Peiman HemattiUniversity of Wisconsin, Madison, Wisconsin, Department of Medicine, Division of Hematology/Oncology.
Amy K KeatingDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Colorado School of Medicine, Colorado, Denver, CO, USA.
David I MarksUniversity Hospitals Bristol NHS Trust, Bristol, UK.
Richard OlssonDepartment of Laboratory Medicine, Division of Therapeutic Immunology, Karolinska Institute, Solna, Sweden.
Bipin N SavaniDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Celalettin UstunDepartment of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minnesota, Minneapolis, MN, USA.
Kirsten M WilliamsChildren's National Medical Center, The George Washington University Medical Center, Washington DC, USA.
Marcelo C PasquiniDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
Christopher C DvorakDepartment of Pediatrics, Division of Allergy, Immunology, and Blood and Marrow Transplantation, University of California, San Francisco, San Francisco, California.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
PB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3M
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS U24 CA076518NHLBI NIH HHS L40 HL138866NHLBI NIH HHS U01 HL069294NHLBI NIH HHS U10 HL069294NICHD NIH HHS K12 HD000850
6 · The paper itself

Abstract

Critically ill pediatric allogeneic hematopoietic cell transplant (HCT) patients may benefit from early and aggressive interventions aimed at reversing the progression of multiorgan dysfunction. Therefore, we evaluated 25 early risk factors for pediatric intensive care unit (PICU) mortality to improve mortality prognostication. We merged the Virtual Pediatric Systems and Center for International Blood and Marrow Transplant Research databases and analyzed 936 critically ill patients ≤21 years of age who had undergone allogeneic HCT and subsequently required PICU admission between January 1, 2009, and December 31, 2014. Of 1532 PICU admissions, the overall PICU mortality rate was 17.4% (95% confidence interval [CI], 15.6% to 19.4%) but was significantly higher for patients requiring mechanical ventilation (44.0%), renal replacement therapy (56.1%), or extracorporeal life support (77.8%). Mortality estimates increased significantly the longer that patients remained in the PICU. Of 25 HCT- and PICU-specific characteristics available at or near the time of PICU admission, moderate/severe pre-HCT renal injury, pre-HCT recipient cytomegalovirus seropositivity, <100-day interval between HCT and PICU admission, HCT for underlying acute myeloid leukemia, and greater admission organ dysfunction as approximated by the Pediatric Risk of Mortality 3 score were each independently associated with PICU mortality. A multivariable model using these components identified that patients in the top quartile of risk had 3 times greater mortality than other patients (35.1% versus 11.5%, P < .001, classification accuracy 75.2%; 95% CI, 73.0% to 77.4%). These data improve our working knowledge of the factors influencing the progression of critical illness in pediatric allogeneic HCT patients. Future investigation aimed at mitigating the effect of these risk factors is warranted.

Indexed as

Critical IllnessHematopoietic Stem Cell TransplantationChildHumansInfantIntensive Care Units, PediatricRegistriesRetrospective StudiesRisk FactorsHematopoietic stem cell transplantationIntensive care unitsOrgan dysfunction scoresPediatricPrognosisSurvival analysis

Identifiers

PMID31563573
PMCPMC6943183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.